drugset / Trial / NCT06031272
Pausing Antiretroviral Treatment Under Structured Evaluation
Phase 1
Active not recruiting
32 enrolled
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of this study is to see if it is safe to give the study antibodies (3BNC117-LS-J and 10-1074-LS-J) by intravenous infusion to people with HIV (PWH), and to see if they cause any side effects. In addition, to see how the study antibodies affect the level of HIV in the blood when participants are not taking regular HIV treatment for an extended period. This extended period of not taking regular HIV treatment is called an analytical treatment interruption (ATI).
Timeline
- Start
- 2024-05-28
- Primary completion
- 2025-10-14
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 10-1074-LS-J | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Teropavimab | Monoclonal antibody | 30 mg/kg | Intravenous |